Current Edition


Taking a Long-Term Approach to Improving Vaccine Trial Recruitment

The groundbreaking mRNA technology used in the COVID-19 vaccine has potential applications in preventing a number of other infectious diseases and is ushering in a …

Continue Reading →

SK advances Gates-backed COVID-19 antiviral spray toward clinic

SK bioscience is stepping up work on a nasal spray to prevent and treat COVID-19. With the Bill & Melinda Gates Foundation kicking in cash, …

Continue Reading →

Pfizer’s COVID pill Paxlovid gets boost in Britain thanks to spot in national trial

Pfizer’s COVID-19 vaccine and antiviral show little sign of slowing down in the pandemic’s third year. Now, the company’s oral therapy is getting a boost …

Continue Reading →

After FDA green lights a second COVID booster, official says another could come in the fall

A few hours after the FDA authorized a fourth dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines, one of its top experts hinted that a …

Continue Reading →

Moderna seeks FDA nod for COVID vaccine in children under 6, starts delayed filing for older kids

Moderna has new data backing the use of its COVID-19 vaccine Spikevax at a low dose in the youngest children under the age of 6, …

Continue Reading →

Teva survey finds COVID has ‘widened the chasm’ on health disparities

By now, it’s no surprise that the global pandemic has worsened long-standing health inequities—and pharma has stepped up with a flood of initiatives to try …

Continue Reading →

AstraZeneca’s Evusheld becomes first FDA-authorized COVID antibody to protect the immunocompromised before exposure

People in the U.S. with conditions that prevent them from building immunity with COVID-19 vaccines will soon have a way to get adequate protection from …

Continue Reading →

Pfizer, BioNTech say omicron partially evades its COVID vaccine but booster can restore protection

The COVID-19 vaccine produced by Pfizer and BioNTech, Comirnaty, provides less protection against the omicron variant than it did against wild-type COVID and other variants, …

Continue Reading →

What would Medicare price negotiations bring to the US? Look to Europe, Lilly CEO Ricks says

When posed with the decades-old question of how drug price reform would affect their operations in the U.S., pharma execs have a ready-made response: Reducing …

Continue Reading →

Amid COVID’s latest surge, Regeneron and Eli Lilly score new antibody supply deals with the U.S.

During a call with analysts last month, Regeneron said it didn’t expect to record additional sales of its COVID-19 antibodies to the United States this …

Continue Reading →